NCT02850289 - APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin | Biotech Hunter

Enrollment

385

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions

Hepatitis C, Chronic

Interventions

DRUG

Pegylated interferon (PEG-INF) alfa-2a

Pegylated interferon (PEG-IFN) alfa-2a will be administered as per investigator's discretion and will be in line with the current product monograph.

DRUG

Ribavirin

Ribavirin will be administered as per investigator's discretion and will be in line with the current product monograph.

Trial Locations (46)

T2N 4N1

Calgary

T5H 4B9

Edmonton

T6G 2C8

Edmonton

T6G2B7

Edmonton

V2S 3N5

Abbotsford

V3V 1Z1

Surrey

V5Z 1H2

Vancouver

V5Z 3P1

Vancouver

V6Z 2C7

Vancouver

V6Z 2K5

Vancouver

V1T 1W9

Vernon

V7S 1X1

West Vancouver

R2W 5L4

Winnipeg

L4M 5G1

Barrie

L6V 1B4

Brampton

M3N 2V7

Downsview

P3E 1B8

Greater Sudbury

L8L 2X2

Hamilton

K7L 5G2

Kingston

N6A 5A5

London

N6A 5R9

London

N6B 2L4

London

L5M 2V8

Mississauga

L3Y 2P6

Newmarket

L1G 2B9

Oshawa

L1J 2J9

Oshawa

K1H 8L6

Ottawa

K1Y 4E9

Ottawa

L4E 4L6

Richmond Hill

Unknown

Richmond Hill

P7B 6V4

Thunder Bay

M5G 2C4

Toronto

M6H 3M1

Toronto

N8X 5A6

Windsor

N9A 1C9

Windsor

H1T 2M4

Montreal

H3A 1A1

Montreal

H4J 1C5

Montreal

J2X 4S7

Montreal

G1L 3L5

Québec

G1R 1S9

Québec

G1R 2J6

Québec

QC G1S 4L8

Québec

J6E 2C3

Saint-Charles-Borromée

S4P 4V6

Regina

S7N 0W8

Saskatoon

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY